Long-term study of patients treated with Inaticabtagene Autoleucel
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study is a long-term follow-up for people who have already received Inaticabtagene Autoleucel, a type of cell therapy. It checks how patients are doing over time, and does not involve any new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received at least one dose of the study drug Inaticabtagene Autoleucel (a type of cell therapy) in a previous clinical trial or as a commercial treatment.
- You must be willing to sign a consent form agreeing to long-term follow-up.
- This study is for people who have already been treated with this specific therapy, not for new patients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
This study is for people who have already been treated with Relma-cel, a type of CAR-T cell therapy for blood cancers. It is not a new treatment but a way to collect more information about how Relma-cel works over time.
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This study follows patients who have had gene-modified T-cell therapy to track their health over time. It does not test a new treatment but helps doctors understand long-term effects.
Hear when a new B-cell Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.